MODELING HEALTH AND ECONOMIC OUTCOMES ASSOCIATED WITH EXENATIDE ONCE-WEEKLY VERSUS INSULIN AND PIOGLITAZONE TREATMENT FOR TYPE-2 DIABETES

被引：0
|
作者：
Gaebler, J. A. [1 ]
Soto-Campos, G. [2 ]
Alperin, P. E. [3 ]
Hoogwerf, B. J. [4 ]
Wintle, M. [1 ]
Maggs, D. [1 ]
Han, J. [1 ]
Blickensderfer, A. [5 ]
Pencek, R. [1 ]
Bruhn, D. [6 ]
Peskin, B. R. [2 ]
机构：
[1] Amylin Pharmaceut Inc, San Diego, CA USA
[2] Archimedes Inc, San Francisco, CA USA
[3] Archimedes Inc, San Diego, CA USA
[4] Eli Lilly & Co, Indianapolis, IN 46285 USA
[5] Amylin Pharmaceut Inc, Chesterfield, MO USA
[6] Eli Lilly & Co, San Diego, CA USA
来源：
VALUE IN HEALTH | 2011年 / 14卷 / 03期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
下载
收藏
页码：A91 / A91
页数：1
相关论文
共 50 条
  • [21] Advances in Diabetes Treatment - Once-Weekly Insulin
    Gottlieb, Peter A.
    Michels, Aaron W.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (22): : 2171 - 2172
  • [22] PROJECTED LONG-TERM CLINICAL AND ECONOMIC OUTCOMES OF EXENATIDE ONCE WEEKLY VERSUS SITAGLIPTIN FOR THE TREATMENT OF TYPE 2 DIABETES IN THE UK
    Beaudet, A.
    Wilson, B.
    Caputo, J.
    Timlin, L.
    VALUE IN HEALTH, 2011, 14 (07) : A476 - A476
  • [23] Life-years, QALYs, costs and numbers needed to treat associated with exenatide once weekly versus insulin and pioglitazone treatment for type 2 diabetes: an Archimedes model simulation
    Alperin, P.
    Gaebler, J. A.
    Soto-Campos, G.
    Hoogwerf, B.
    Wintle, M.
    Maggs, D.
    Blickensderfer, A.
    Bruhn, D.
    Peskin, B.
    DIABETOLOGIA, 2011, 54 : S327 - S327
  • [24] Exenatide once weekly in type 2 diabetes
    Scheen, Andre J.
    LANCET, 2008, 372 (9645): : 1197 - 1198
  • [25] Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus
    Seewoodhary, Jason
    Griffin, Leanne
    Bain, Stephen C.
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2010, 3 : 165 - 172
  • [26] Exenatide extended-release: A once-weekly option for patients with type 2 diabetes
    Anderson, Zachary L.
    Clements, Jennifer N.
    JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS, 2014, 27 (06): : 44 - 46
  • [27] COST-EFFECTIVENESS OF EXENATIDE ONCE WEEKLY VERSUS INSULIN GLARGINE AND LIRAGLUTIDE FOR THE TREATMENT OF TYPE 2 DIABETES IN GREECE
    Tzanetakos, C.
    Bargiota, A.
    Kourlaba, G.
    Maniadakis, N.
    VALUE IN HEALTH, 2016, 19 (07) : A672 - A672
  • [28] Cost Effectiveness of Exenatide Once Weekly Versus Insulin Glargine and Liraglutide for the Treatment of Type 2 Diabetes Mellitus in Greece
    Tzanetakos, Charalampos
    Bargiota, Alexandra
    Kourlaba, Georgia
    Gourzoulidis, George
    Maniadakis, Nikos
    CLINICAL DRUG INVESTIGATION, 2018, 38 (01) : 67 - 77
  • [29] Cost Effectiveness of Exenatide Once Weekly Versus Insulin Glargine and Liraglutide for the Treatment of Type 2 Diabetes Mellitus in Greece
    Charalampos Tzanetakos
    Alexandra Bargiota
    Georgia Kourlaba
    George Gourzoulidis
    Nikos Maniadakis
    Clinical Drug Investigation, 2018, 38 : 67 - 77
  • [30] Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes
    Arslanian, Silva A.
    Hannon, Tamara
    Zeitler, Philip
    Chao, Lily C.
    Boucher-Berry, Claudia
    Barrientos-Perez, Margarita
    Bismuth, Elise
    Dib, Sergio
    Cho, Jang Ik
    Cox, David
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (05): : 433 - 443
12345